Table 3.

Concentrations of asprosin (ASP) in participants’ blood plasma in the aerobic group (EG1), aerobic-resistance group (EG2), and control group (CG).

	Group	Week 1, baseline	Week 6, intervention	Week 12, intervention	Week 16, follow up	Between measurements comparison p-value and ES
		X® ± SD	X® ± SD	X® ± SD	X® ± SD	Test ANOVA (ES)	d 6–1 (ES)	d 12–1 (ES)	d 16–1 (ES)
ASP (ng/ml)	EG1	30.18 ± 7.86	26.32 ± 8.28	28.07 ± 9.54	28.26 ± 9.73	0.15 (0.03)	0.03 (0.68)	0.37(0.26)	0.13 (0.45)
	EG2	27.83 ± 8.11	29.59 ± 5.00	29.78 ± 10.98	38.57 ± 24.94	0.33 (0.08)	0.84 (0.07)	0.77 (0.10)	0.38 (0.31)
	CG	28.10 ± 6.25	27.53 ± 8.88	31.18 ± 8.7	38.90 ± 14.17	< 0.001 (0.34)	0.78 (0.10)	0.76 (0.12)	0.01 (1.35)
	p-value between groups	0.68	0.56	0.73	0.22

d 6–1, d 12–1, d 16–1 – differences in results obtained after 6 and 12 weeks of interventions, respectively, and after 4 weeks of follow-up in relation to measurements taken before interventions, X® mean, SD standard deviation, p < 0.05 – statistically significant difference, ES effect size.